NO20074267L - Konjugater av biologisk aktive proteiner som har en modifisert in vivo halveringstid - Google Patents

Konjugater av biologisk aktive proteiner som har en modifisert in vivo halveringstid

Info

Publication number
NO20074267L
NO20074267L NO20074267A NO20074267A NO20074267L NO 20074267 L NO20074267 L NO 20074267L NO 20074267 A NO20074267 A NO 20074267A NO 20074267 A NO20074267 A NO 20074267A NO 20074267 L NO20074267 L NO 20074267L
Authority
NO
Norway
Prior art keywords
biologically active
life
modified
polypeptide
conjugates
Prior art date
Application number
NO20074267A
Other languages
English (en)
Norwegian (no)
Inventor
Marc Besman
Stewart Chipman
David Leung
Original Assignee
Cell Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Therapeutics Inc filed Critical Cell Therapeutics Inc
Publication of NO20074267L publication Critical patent/NO20074267L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
NO20074267A 2005-01-25 2007-08-21 Konjugater av biologisk aktive proteiner som har en modifisert in vivo halveringstid NO20074267L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64711905P 2005-01-25 2005-01-25
US71258505P 2005-08-30 2005-08-30
PCT/US2006/002501 WO2006081249A2 (en) 2005-01-25 2006-01-25 Conjugates of biologically active proteins having a modified in vivo half-life

Publications (1)

Publication Number Publication Date
NO20074267L true NO20074267L (no) 2007-09-28

Family

ID=36644921

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074267A NO20074267L (no) 2005-01-25 2007-08-21 Konjugater av biologisk aktive proteiner som har en modifisert in vivo halveringstid

Country Status (14)

Country Link
US (2) US8129348B2 (pt)
EP (1) EP1841787A2 (pt)
JP (2) JP5735194B2 (pt)
KR (1) KR101608083B1 (pt)
CN (1) CN103172747A (pt)
AU (1) AU2006208199B2 (pt)
BR (1) BRPI0606934A2 (pt)
CA (1) CA2595695A1 (pt)
IL (1) IL184763A (pt)
MX (1) MX2007008982A (pt)
NO (1) NO20074267L (pt)
NZ (1) NZ556726A (pt)
RU (1) RU2007132188A (pt)
WO (1) WO2006081249A2 (pt)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006081249A2 (en) * 2005-01-25 2006-08-03 Cell Therapeutics, Inc. Conjugates of biologically active proteins having a modified in vivo half-life
US7846445B2 (en) 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
EP1996937A4 (en) † 2006-03-06 2009-04-08 Amunix Inc GENETIC PACKS AND USES THEREOF
ES2529315T5 (es) † 2006-03-06 2024-02-23 Amunix Operating Inc Polímeros recombinantes no estructurados y usos de los mismos
EP2009103A1 (en) 2007-03-16 2008-12-31 Ebewe Pharma Ges.m.b.H. Nfg. KG Neurotrophic peptides
US8592374B2 (en) 2007-03-16 2013-11-26 Research Foundation For Mental Hygiene, Inc. Neurotrophic peptides
DK2173890T3 (da) 2007-06-21 2011-06-27 Univ Muenchen Tech Biologisk aktive proteiner med forhøjet stabilitet in vivo og/eller in vitro
AU2013203326B2 (en) * 2007-06-21 2013-08-01 Technische Universitat Munchen Biological active proteins having increased in vivo and/or in vitro stability
KR20100058541A (ko) 2007-08-15 2010-06-03 아뮤닉스 인코포레이티드 생물학적 활성 폴리펩티드의 특성을 변경하기 위한 조성물 및 방법
CN101939329A (zh) * 2007-08-30 2011-01-05 滑铁卢大学 以氨基酸配对为基础的自组装肽和方法
EA201101015A1 (ru) 2008-12-29 2012-02-28 Лонца Брен Са Способ получения бивалирудина
JP5499296B2 (ja) * 2009-02-03 2014-05-21 国立大学法人東京農工大学 細胞の吸着を制御可能なポリペプチド
ES2610356T3 (es) 2009-02-03 2017-04-27 Amunix Operating Inc. Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos
US8680050B2 (en) 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
PT2440228T (pt) 2009-06-08 2018-12-24 Amunix Operating Inc Polipéptidos de regulação da glicose e métodos de preparação e utilização dos mesmos
WO2011028229A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor ix compositions and methods of making and using same
US8557961B2 (en) 2010-04-02 2013-10-15 Amunix Operating Inc. Alpha 1-antitrypsin compositions and methods of making and using same
WO2011144756A1 (en) 2010-05-21 2011-11-24 Xl-Protein Gmbh Biosynthetic proline/alanine random coil polypeptides and their uses
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
NZ611076A (en) 2010-12-01 2015-09-25 Alderbio Holdings Llc Anti-ngf compositions and use thereof
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US20140323402A1 (en) 2011-08-12 2014-10-30 Ascendis Phama A/S Protein Carrier-Linked Prodrugs
CA2864904C (en) 2012-02-15 2023-04-25 Amunix Operating Inc. Factor viii compositions and methods of making and using same
EP3549953A1 (en) 2012-02-15 2019-10-09 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
CN107496932A (zh) 2012-02-27 2017-12-22 阿穆尼克斯运营公司 Xten缀合组合物和制造其的方法
NZ701573A (en) 2012-05-17 2017-04-28 Extend Biosciences Inc Carriers for improved drug delivery
CA2890110C (en) 2012-11-01 2023-05-02 Factor Bioscience Inc. Methods and products for expressing proteins in cells
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
EP3256585A4 (en) 2015-02-13 2018-08-15 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
CN104988107B (zh) * 2015-05-19 2018-06-08 中国农业科学院兰州兽医研究所 一种高效表达口蹄疫病毒抗原基因的重组乳酸杆菌及其制备方法和应用
EP3303380B1 (en) * 2015-06-02 2020-01-15 Novo Nordisk A/S Insulins with polar recombinant extensions
WO2017024060A1 (en) 2015-08-03 2017-02-09 Biogen Ma Inc. Factor ix fusion proteins and methods of making and using same
IL307276A (en) 2015-08-28 2023-11-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
MA43348A (fr) 2015-10-01 2018-08-08 Novo Nordisk As Conjugués de protéines
US10576167B2 (en) 2016-08-17 2020-03-03 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
KR102613874B1 (ko) 2017-01-30 2023-12-15 알렉시온 파마슈티칼스, 인코포레이티드 1가 항-프로페르딘 항체 및 항체 단편
EP3606560A2 (en) 2017-04-05 2020-02-12 Novo Nordisk A/S Oligomer extended insulin-fc conjugates
US10501404B1 (en) 2019-07-30 2019-12-10 Factor Bioscience Inc. Cationic lipids and transfection methods
US20220370546A1 (en) * 2019-11-05 2022-11-24 Kyoto University Peptide, composition, and method for treating, preventing, or ameliorating mood disorder
CN112608366A (zh) * 2020-12-31 2021-04-06 中国药科大学 超正电荷聚多肽及其制备方法、应用
CN113480667B (zh) * 2021-08-17 2023-03-28 长春萤火虫生物科技有限公司 一种人粒细胞集落刺激因子突变体重组融合蛋白及其制备方法和应用
WO2024128079A1 (ja) * 2022-12-16 2024-06-20 東亞合成株式会社 合成ペプチド及び構築物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
AU648020B2 (en) 1989-02-21 1994-04-14 Washington University Modified forms of reproductive hormones
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6455678B1 (en) 1996-04-26 2002-09-24 Amcell Corporation Human hematopoietic stem and progenitor cell antigen
CN1240479A (zh) * 1996-07-09 2000-01-05 安姆根有限公司 截短的可溶性肿瘤坏死因子i－型和ii－型受体
WO1998049198A1 (en) * 1997-04-30 1998-11-05 Enzon, Inc. Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
ES2341217T3 (es) 1999-01-19 2010-06-17 Maxygen, Inc. Recombinacion de acidos nucleicos mediada por oligonucleotidos.
CZ299516B6 (cs) 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
US6831158B2 (en) 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
AU2001267337A1 (en) * 2000-06-30 2002-01-14 Maxygen Aps Peptide extended glycosylated polypeptides
EP1497331A2 (en) 2002-01-14 2005-01-19 William Herman Multispecific binding molecules
CN100472488C (zh) 2004-07-06 2009-03-25 株式会社Ntt都科摩 消息发送系统和消息发送方法
DE102004049479A1 (de) 2004-10-11 2006-04-13 Scil Proteins Gmbh Proteinkonjugate zur Verwendung in Therapie, Diagnose und Chromatographie
CN101111516B (zh) * 2005-01-25 2013-02-27 细胞治疗学公司 体内半衰期改变的生物活性蛋白质偶联物
WO2006081249A2 (en) * 2005-01-25 2006-08-03 Cell Therapeutics, Inc. Conjugates of biologically active proteins having a modified in vivo half-life

Also Published As

Publication number Publication date
IL184763A (en) 2013-05-30
US20120252717A1 (en) 2012-10-04
WO2006081249A2 (en) 2006-08-03
IL184763A0 (en) 2007-12-03
MX2007008982A (es) 2007-12-06
RU2007132188A (ru) 2009-03-10
US8129348B2 (en) 2012-03-06
NZ556726A (en) 2011-04-29
AU2006208199B2 (en) 2012-06-07
WO2006081249A8 (en) 2007-09-13
US8748577B2 (en) 2014-06-10
AU2006208199A1 (en) 2006-08-03
KR101608083B1 (ko) 2016-04-01
WO2006081249A3 (en) 2007-02-01
JP2008528002A (ja) 2008-07-31
KR20070119622A (ko) 2007-12-20
EP1841787A2 (en) 2007-10-10
JP5735194B2 (ja) 2015-06-17
WO2006081249A9 (en) 2007-07-26
JP2013100292A (ja) 2013-05-23
CA2595695A1 (en) 2006-08-03
CN103172747A (zh) 2013-06-26
BRPI0606934A2 (pt) 2017-07-11
US20090298762A1 (en) 2009-12-03

Similar Documents

Publication Publication Date Title
NO20074267L (no) Konjugater av biologisk aktive proteiner som har en modifisert in vivo halveringstid
WO2006127896A3 (en) Glycopegylated factor ix
CY1119243T1 (el) Φαρμακοτεχνικες μορφες ανταγωνιστη του vegf
ES2397852T3 (es) Antagonistas y conjugados de péptidos CGRP
WO2006074467A3 (en) Glycopegylated granulocyte colony stimulating factor
AU2012255119B2 (en) Improved peptide pharmaceuticals for insulin resistance
NO20080970L (no) Glykopegylert faktor VII og faktor VIIA
SI1180121T1 (en) Long lasting insulinotropic peptides
RS54215B1 (en) COMPOSITIONS AND PROCEDURES FOR DIAGNOSIS AND TREATMENT OF CANCER
WO2005055946A3 (en) Glycopegylated granulocyte colony stimulating factor
WO2005056760A3 (en) Glycopegylated follicle stimulating hormone
BRPI0717505B8 (pt) conjugado de peptídeo e formulação farmacêutica
NO20082716L (no) Sammensetninger og fremgangsmater for fremstilling av en sammensetning
UA96916C2 (ru) Конъюгат полипептида и синтетически сульфатованого пентасахарида, фармацевтическая композиция на его основе
DK1329458T5 (da) Peptider som sænker blodglucoseniveauer
WO2006113681A3 (en) Plant-derived elastin binding protein ligands and methods of using the same
SE9901379D0 (sv) Receptor structures
CY1117104T1 (el) Διαλυτες γλυκοσαμινογλυκανασες και μεθοδοι παρασκευης και χρησης των διαλυτων γλυκοσαμινογλυκανασων
EP3118218A3 (en) Fusion proteins for blood-brain barrier delivery
MXPA03011094A (es) Citotoxinas, profarmacos, ligadores, y estabilizadores utiles para ello.
WO2006127910A3 (en) Glycopegylated erythropoietin formulations
CY1113299T1 (el) Πολυπεπτιδια απροτινινης για τη μεταφορα μιας ενωσης μεσα στον αιματοεγκεφαλικο φραγμο
MX2007013626A (es) Anticuerpos dirigidos contra el peptido beta amiloide y procedimientos que usan los mismos.
WO2007067979A3 (en) Targeting vector-phospholipid conjugates
WO2003049684A3 (en) Pseudo-antibody constructs

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application